Galantamine
- Generic Name
- Galantamine
- Brand Names
- Razadyne
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO3
- CAS Number
- 357-70-0
- Unique Ingredient Identifier
- 0D3Q044KCA
- Background
Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as Galanthus nivalis. Galantam...
- Indication
Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.
- Associated Conditions
- Mild to Moderate Dementia Due to Alzheimer's Disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia
- Associated Therapies
- -
Cognitive Enhancement as a Target for Cocaine Pharmacotherapy
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- Yale University
- Target Recruit Count
- 93
- Registration Number
- NCT01531153
- Locations
- 🇺🇸
Department of Veterans Affairs, West Haven, Connecticut, United States
Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2021-08-27
- Target Recruit Count
- 47
- Registration Number
- NCT01508494
- Locations
- 🇫🇷
Service de Neurologie, CHU Toulouse Purpan, Toulouse, France
Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 102
- Registration Number
- NCT01478633
Galantamine Effects on Nicotine Responses in Smokers
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Yale University
- Target Recruit Count
- 12
- Registration Number
- NCT01417429
- Locations
- 🇺🇸
Department of Veterans Affairs, West Haven, Connecticut, United States
Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 28
- Registration Number
- NCT01372280
Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 24
- Registration Number
- NCT01372306
Comparative Research of Alzheimer's Disease Drugs
- Conditions
- Interventions
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 200
- Registration Number
- NCT01362686
- Locations
- 🇺🇸
Touchpoint, Fishers, Indiana, United States
🇺🇸Methodist Center for Geriatric Medicine, Indianapolis, Indiana, United States
🇺🇸University Clinical Neurology, Indianapolis, Indiana, United States
Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance
- Conditions
- Interventions
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2017-05-03
- Target Recruit Count
- 84
- Registration Number
- NCT01194336
- Locations
- 🇺🇸
Walter Reed Army Institute of Research, Silver Spring, Maryland, United States
The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Janssen-Cilag, S.A.
- Target Recruit Count
- 1
- Registration Number
- NCT01181921
Galantamine Treatment for Nonfluent Aphasia in Stroke Patients
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2010-05-24
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 8
- Registration Number
- NCT01129479
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.